Walleye Capital’s Filana Therapeutics FLNA Stock Holding History

Walleye Capital’s Portfolio FLNA Stock Details FLNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$24K	Buy	+20,200	New	+$28.8K	﹤0.01%	4352

Other funds holding FLNA

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

GMT Capital Atlanta, Georgia $1.92B AUM 70.51% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

Walleye Capital's FLNA Position: Q4 2024 in Review

Walleye Capital sold out of Filana Therapeutics (FLNA) in Q4 2024, closing a stake of 2,985 shares — an estimated $87.8K sold.

Walleye Capital first reported a position in FLNA in Q2 2023 and held it in 2 quarters. The position peaked at $136K in Q2 2023. 137 funds tracked by Wall St. Rank hold FLNA as of Q4 2024.

Walleye Capital reported no remaining Filana Therapeutics position as of Q4 2024 after selling out during the quarter.
Walleye Capital sold 2,985 Filana Therapeutics shares in Q4 2024, an estimated $87.8K.
Walleye Capital first reported a position in Filana Therapeutics in Q2 2023 and held it in 2 quarters.
Walleye Capital's Filana Therapeutics position peaked at $136K in Q2 2023.
137 funds tracked by Wall St. Rank held Filana Therapeutics as of Q4 2024.

Based on Walleye Capital's 13F filing for Q4 2024, filed 13 Feb 2025.